High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc): Long-Term Survivors Show Continued Improvement of Function and Skin with Stability in the Lungs.
Peter A. McSweeney(Mesoblast (United States)), Richard A. Nash(Colorado Blood Cancer Institute), C.S. Chen(Loma Linda University), Gretchen Henstorf(Fred Hutch Cancer Center), Muneer H. Abidi(Spectrum Health), Mark H. Wener(University of Washington), Daniel E. Furst(University of California, Los Angeles), Leslie J. Crofford(Vanderbilt University Medical Center), Mayes Maureen(University of Houston), Philip J. Mease(Providence College), Jan Storek(University of Washington), Nelson Lee(University of Toronto), Julie Lee(Aneurin Bevan University Health Board), Kevin T. McDonagh(University of Michigan), Leona Holmberg, Theodore A. Gooley(Leipzig University), Keith M. Sullivan(Duke Medical Center)
Cited by 3
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k